This study focuses on individuals living with Sickle Cell Disease, a condition that affects red blood cells, causing them to become misshapen like a crescent moon. This shape can lead to complications such as a vaso-occlusive crisis, which is a painful episode caused by blood cells getting stuck in small blood vessels. The purpose of the study is to assess the safety of the drug anumigilimab, also known as CSL324.

Participants will be assigned to receive either anumigilimab or a placebo through a subcutaneous injection, which means the medication is administered just under the skin. The study uses a double-blind method, meaning neither the participants nor the researchers know which substance is being given at any given time. This process helps ensure that the results are as accurate as possible.

During the course of the study, the effects of the medication will be monitored over time. This includes observing any adverse events, which are unintended side effects or medical problems that may occur during the treatment. The study will track how the body responds to the injection and monitor general health markers to ensure participant safety.